simulation:
  - step: 1
    level: organism
    consequence: stage III colon adenocarcinoma diagnosis
    probability: 100
    explanation: The patient is diagnosed with stage III colon adenocarcinoma on the right side of the colon, with poorly differentiated differentiation histology, metastasis, and no signs of carcinomatosis.
  - step: 2
    level: organ
    consequence: initiation of standard of care treatment
    probability: 100
    explanation: Given the general effectiveness of colon adenocarcinoma therapies, the patient undergoes an optimal standard of care treatment plan, which typically includes surgery, chemotherapy, and possibly radiation therapy.
  - step: 3
    level: cellular
    consequence: reduction in tumor size and metastatic potential
    probability: 85
    explanation: The standard of care treatment plan targets cancer cells, leading to a reduction in tumor size and a decrease in the potential for further metastasis. However, the poorly differentiated histology may make the tumor more aggressive and resistant to treatment.
  - step: 4
    level: molecular
    consequence: molecular changes in response to treatment
    probability: 80
    explanation: As the tumor cells are exposed to chemotherapy and radiation, molecular changes occur within the cells, including DNA damage, cell cycle arrest, and apoptosis. However, the poorly differentiated histology may result in a higher likelihood of treatment resistance and tumor recurrence.
  - step: 5
    level: cellular
    consequence: potential emergence of treatment-resistant cells
    probability: 60
    explanation: Due to the poorly differentiated histology and the aggressive nature of the tumor, there is a possibility that some cancer cells may develop resistance to the standard of care treatment, leading to tumor recurrence and progression.
  - step: 6
    level: organ
    consequence: monitoring for tumor recurrence and progression
    probability: 100
    explanation: The patient will be closely monitored for signs of tumor recurrence and progression through regular imaging and blood tests, allowing for early detection and intervention if necessary.

conclusion:
  outcome: 8 months of progression-free survival
  explanation: Based on the provided examples and considering the patient's age, tumor location, histology, and metastasis status, an estimated progression-free survival of 8 months is expected under an optimal standard of care treatment plan. This estimate takes into account the aggressive nature of the tumor due to its poorly differentiated histology and the potential for treatment resistance.